Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Zakharia, Y. [1 ]
Thomaidou, D. [2 ]
Li, B. [3 ]
Siu, G. [3 ]
Levin, R. [4 ]
Vlahiotis, A. [4 ]
Zanotti, G. [5 ]
机构：
[1] Univ Iowa Hosp & Clin, Holden Comprehens Canc Ctr, Iowa City, IA USA
[2] Pfizer Inc, Global Med Affairs, Pfizer Oncol, Hellas, Greece
[3] Pfizer Inc, Global Prod Dev, Global Biometr & Data Management, New York, NY USA
[4] Pfizer Inc, Real World Evidence Ctr Excellence, New York, NY USA
[5] Pfizer Inc, Hlth Econ & Outcome Res, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111P
引用
收藏
页码：S1423 / S1424
页数：2
相关论文
共 50 条
  • [21] Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)
    Jonasch, E.
    Bair, A.
    Chen, Y.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
    Chaudhuri, T.
    Upadhyay, A.
    Bankira, J.
    Panda, R.
    Pandey, V.
    Mitra, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1567 - S1567
  • [23] Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease
    Stativko, O.
    Pokataev, I.
    Fedyanin, M.
    Kravchuk, D. A.
    Andreiashkina, I.
    Polshina, N.
    Volkonskiy, M. V.
    Bystrov, A.
    Salpagarov, N.
    Antonova, T.
    Zhukova, L.
    Volkova, M. I.
    Stroyakovskiy, D.
    Galkin, V. N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1514 - S1515
  • [24] First-line Axitinib plus Pembrolizumab in advanced renal cell carcinoma: retrospective real world data from a multicentre patient cohort
    Darr, Christopher
    Stelmach, Ramona
    Schlack, Katrin
    Dinkel, Hendrik
    Paffenholz, Pia
    Ivanyi, Philipp
    Wiegmann, Jonas
    Schulz, Anton
    Kramer, Mario
    Schnabel, Marco
    Rinderknecht, Emily
    Handke, Analena
    Hilser, Thomas
    Heidenreich, Axel
    Hadaschik, Boris
    Zschaebitz, Stefanie
    Gruenwald, Viktor
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 79 - 80
  • [25] Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab plus axitinib vs. ipilimumab plus nivolumab
    Shah, Neil J.
    Sura, Sneha D.
    Shinde, Reshma
    Shi, Junxin
    Singhal, Puneet
    Perini, Rodolfo F.
    Motzer, Robert J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 459.e1 - 459.e8
  • [26] Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab.
    Zarrabi, Kevin
    Handorf, Elizabeth A.
    Miron, Benjamin
    Zibelman, Matthew R.
    Anari, Fern
    Ghatalia, Pooja
    Plimack, Elizabeth R.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
    Mollica, Veronica
    Di Nunno, Vincenzo
    Massari, Francesco
    CHINESE CLINICAL ONCOLOGY, 2019, 8
  • [28] Pembrolizumab + axitinib beyond first-line therapy for mRCC
    Tim Thomas
    Nature Reviews Urology, 2023, 20 : 131 - 131
  • [29] Axitinib as first-line therapy in metastatic renal cell carcinoma
    Nozawa, Masahiro
    Uemura, Hirotsugu
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 555 - 557
  • [30] Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
    Chau, Vincent
    Bilusic, Marijo
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7321 - 7330
12345